수두증 션트 시장 보고서 : 유형별, 제품 유형별, 연령층별, 최종사용자별, 지역별(2026-2034년)

The global hydrocephalus shunts market size reached USD 483.1 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 651.8 Million by 2034, exhibiting a growth rate (CAGR) of 3.28 % during 2026-2034. T he market is primarily driven by the rising incidence of hydrocephalus, advanced healthcare infrastructure, and technological innovations in shunts design. Moreover, increasing cases of congenital hydrocephalus and rapid proliferation of pediatric population are significantly driving the market growth.

HYDROCEPHALUS SHUNTS MARKET ANALYSIS:

• Major Market Drivers: The hydrocephalus shunts market size is driven by advancing healthcare infrastructure, escalating prevalence of hydrocephalus, and technological advancements in shunt development. In line with this, the growing geriatric and pediatric populations are substantially aiding the market toward expansion. Additionally, preferable money repayment policies and surge in awareness about early treatment and detection methods further spur market growth. Heavy investments in research of neurogenerative diseases, including hydrocephalus, prompting innovations and manufacturing of effective shunt solutions, also play a pivotal role in expanding the hydrocephalus shunts market size.
• Key Market Trends: Some of the major hydrocephalus shunts market trends involve rapid integration of cutting-edge technology, including anti-siphon and programmable shunts, spurred by their improved patient outcomes. There is an escalating demand in emerging economies primarily due to enhancing healthcare expenditure and infrastructure. Surge in pediatric hydrocephalus incidents is also propelling the demand for specialized shunts. Moreover, substantial investments in R&D are driving the creation of innovative product designs. Concurrently, heightened awareness and improved diagnostic rates are fueling the market growth by identifying cases that require prompt intervention.
• Geographical Trends: North America is depicting a robust growth in the global hydrocephalus shunts market analysis due to the rising cases of hydrocephalus in the region, coupled with superior healthcare systems. The United Sates leads in the research and development of hydrocephalus shunts solutions and the widespread adoption of innovative medical equipment. Advantageous reimbursement protocols and a strong network of professional healthcare providers further boost this market, establishing North America as a dominant region in the global hydrocephalus shunt market.
• Competitive Landscape: Some of the major market players in the hydrocephalus shunts industry include Argi Grup, CereVasc, Inc., Christoph Miethke GmbH & Co. KG (B. Braun Group), Hpbio, Integra LifeSciences Corporation, Kaneka Medix Corporation, Medtronic plc, Neutral Pharma Pvt. Ltd, Sophysa, and Spiegelberg GmbH & Co. KG., among many others.
• Challenges and Opportunities: The prime challenges witnessed in the global hydrocephalus shunts market overview include requisite technological advancements, increased revision rates, and critical complications. Nonetheless, such challenges offer opportunities for innovations, especially in manufacturing biocompatible and programmable shunts that have lower revision rates. The increasing diagnosis and awareness of hydrocephalus, together with proliferating healthcare infrastructure in emerging countries, further generate substantial growth opportunities. Moreover, funding in research institutes and organizations can enhance competitiveness and positive patient outcomes.

HYDROCEPHALUS SHUNTS MARKET TRENDS:

Increasing Congenital Cases and Pediatric Population

A significant trend in the global hydrocephalus shunts market share is the increasing prevalence of congenital hydrocephalus among infants and children. In addition, rapid growth in pediatric population is also playing a pivotal role in market dynamics. According to The World Counts, each day 385,000 babies are born, i.e., 140 million a year. The heightening incidents of congenital cases has boosted the demand for pediatric shunt solutions. According to John Hopkins Hospital, 1 or 2 of every 1000 infants born in U.S. have congenital hydrocephalus. As a result, manufacturers are currently emphasizing on designing specialized shunts for children and infants, acknowledging the distinct physiological and anatomical needs of this age group.

Rapid Adoption of Advanced Technologies

The global hydrocephalus shunts market is witnessing a notable trend towards the escalating adoption of advanced technologies, including anti-siphon and programmable shunts. Such innovations improve patient outcomes by permitting accurate adjustments of cerebrospinal fluid flow. According to a research article published in the Journal of Neurosurgery, programmable shunts depict lower revision rates than nonprogrammable shunts for the treatment of hydrocephalus. Consequently, programmable shunts are proven to be more cost-efficient. The research showed that 7% of patients with programmable shunts needed revisions, while 21.6% of patients with nonprogrammable shunts required revisions. Additionally, the incorporation of remote monitoring and telehealth systems is further driving adoption by improving post-operative care and lowering the need for frequent hospital visits.

Increasing Product Prevalence in Emerging Economies

The global hydrocephalus shunts market share is witnessing a positive outlook in emerging market principally due to increase in healthcare spending and enhanced healthcare infrastructure. Countries like China and India are undergoing elevated adoption rates of hydrocephalus shunts primarily because of heightening patient awareness and improved medical facilities. As per industry reports, Asia Pacific is projected to depict a robust economic growth in 2024 with India's GDP estimated to grow by 5%. The market expansion is further propelled by government initiatives to enhance healthcare facilities and the strengthening presence of major companies in these economies, targeting to address the unmet medical demands.

HYDROCEPHALUS SHUNTS MARKET SEGMENTATION:

Breakup by Type:

• Ventriculo-Peritoneal
• Ventriculo-Atrial
• Ventriculo-Pleural
• Lumbo-Peritoneal

Ventriculo-peritoneal accounts for the majority of the market share

The ventriculo-peritoneal (VP) represents the majority of the global hydrocephalus shunts market share as it is reliable, highly effective, and is largely accepted in clinical applications. VP shunts demonstrate high success rates in patients with hydrocephalus, aiding in strengthening its dominance in the market dynamics. The widespread utilization of VP shunts in adults as well as pediatrics further facilitate their market growth. As per a clinical report, approximately 750,000 individuals are diagnosed with hydrocephalus, while 160,000 VP shunts are implanted each year globally. Moreover, the robust support from medical professionals and advantageous healthcare policies assists in sustaining hydrocephalus shunts market share and growth.

Breakup by Product Type:

• Hydrocephalus Valves
  • Adjustable Pressure Valves
  • Fix Pressure Valves
• Hydrocephalus Catheters

Hydrocephalus valves hold the largest share of the industry

Hydrocephalus valves play a critical role in regulating the flow of cerebrospinal fluid. Valves are integral component of hydrocephalus shunt system as they aid in maintaining intracranial pressure. Adjustable pressure valves have flexible built, designed to address pressure settings as per the patient needs. Fixed pressure valves are comparatively less versatile but are cost-efficient and reliable. Advancements in manufacturing technology of valves and innovations further strengthen the segment's growth in the global hydrocephalus shunts market share. For instance, Integra LifeSciences has innovated the valves design by manufacturing various variants of fixed pressure valves, including Ultra VS valves, Pudenz Valves, Mishler On/Off valves, and CODMAN HAKIM Precision Fixed Pressure Valves.

Breakup by Age Group:

• Infants
• Children
• Adults

Children represent the leading market segment

Children hold the largest segment in the global hydrocephalus shunts market share due to an elevated prevalence of congenital hydrocephalus and the intense demand for early detection and treatment. According to the National Institutes of Health, it is estimated that each year approximately 400,000 new cases of pediatric hydrocephalus will develop globally. Furthermore, according to a research article published in the Journal of Neurosurgey, Asia also depicts prevalence of pediatric hydrocephalus. In the study, 29% of nonpostinfectious hydrocephalus and 10.7% of postinfectious hydrocephalus were identified across Asia. Specialized shunt systems and development in pediatric neurosurgery for children plays a pivotal role in hydrocephalus shunts market dynamics. Additionally, intensifying awareness about neurogenerative diseases in children and enhanced diagnostics techniques facilitates the segment dominance.

Breakup by End User:

• Hospitals
• Ambulatory Surgical Centers

Hospitals exhibit a clear dominance in the market

Hospitals hold the largest segment as an end user in the global hydrocephalus shunts market forecast because of their superior medical infrastructure, ability to execute critical surgeries, and competent healthcare professionals. Hospitals greatly profit from elevated patient inflow, particularly for critical hydrocephalus cases that demand specialized treatments. According to Hydrocephalus Association, pediatric hydrocephalus accounts for over 40,000 hospital admissions annually, with nearly 10,000 of these admissions resulting from shunt malfunctions. Moreover, facilities like thorough post-surgical care and advanced technologies also fortifies their position in the hydrocephalus shunt market dynamics. Additionally, strategic partnerships between manufacturers and hospitals facilitates a reliable supply chain, improving latter's pivotal role in this market share.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest hydrocephalus shunts market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for hydrocephalus shunts.

North America is the dominant region in the global hydrocephalus shunts market share primarily due to increasing prevalence of hydrocephalus and cutting-edge healthcare infrastructure. According to USF Health, more than 800,000 Americans are suffering with hydrocephalus, while 1%-5% patients that are suffering with dementia are estimated to have hydrocephalus. The region, particularly United States, is leading in research and development sector and extensive utilization of advanced medical technologies. For instance, Indiana University (IU) in Indianapolis was granted with USD 243 million research fund from the National Institutes of Health in 2023. IU is growing rapidly in R&D and has established Hydrocephalus Research Center that aims to discover hydrocephalus solutions. Canada also has a substantial contribution in the regional market dynamics due to rising patient awareness and robust healthcare policies in the country. This regional domination is also strengthened by preferable pay back policies and an entrenched healthcare providers network.

COMPETITIVE LANDSCAPE:

The global hydrocephalus shunts market outlook is represented by an intense competition due to the presence of key companies that are dominating the market share through broad product portfolios, innovative technologies, and strategic acquisitions and partnerships. For instance, in July 2023, CereVasc formed a strategic partnership with LianMedical, a China-based medical device company, to release its eShunt system and other related products to providers and patients in East Asian countries China, Hong Kong, Taiwan, and Macaw. Emerging companies are establishing their positions by emphasizing on cost-efficient product formulations and advancements in technology. Regional competitors also contribute substantially, utilizing regulatory policies and local market expertise. Robust research and development, coupled with continuous striving to improve patient outcomes, further fuel the competition and contribute to market evolution.

The report provides a comprehensive analysis of the competitive landscape in the global hydrocephalus shunts market with detailed profiles of all major companies, including:

• Argi Grup
• CereVasc, Inc.
• Christoph Miethke GmbH & Co. KG (B. Braun Group)
• Hpbio
• Integra LifeSciences Corporation
• Kaneka Medix Corporation
• Medtronic plc
• Neutral Pharma Pvt. Ltd
• Sophysa
• Spiegelberg GmbH & Co. KG.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global hydrocephalus shunts market in 2025?

2. What is the expected growth rate of the global hydrocephalus shunts market during 2026-2034?

3. What has been the impact of COVID-19 on the global hydrocephalus shunts market?

4. What are the key factors driving the global hydrocephalus shunts market?

5. What is the breakup of the global hydrocephalus shunts market based on the type?

6. What is the breakup of the global hydrocephalus shunts market based on the product type?

7. What is the breakup of the global hydrocephalus shunts market based on the age group?

8. What is the breakup of the global hydrocephalus shunts market based on the end user?

9. What are the key regions in the global hydrocephalus shunts market?

10. Who are the key players/companies in the global hydrocephalus shunts market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Hydrocephalus Shunts Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Ventriculo-Peritoneal
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Ventriculo-Atrial
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Ventriculo-Pleural
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Lumbo-Peritoneal
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Product Type

• 7.1 Hydrocephalus Valves
  • 7.1.1 Market Trends
  • 7.1.2 Key Segments
    • 7.1.2.1 Adjustable Pressure Valves
    • 7.1.2.2 Fix Pressure Valves
  • 7.1.3 Market Forecast
• 7.2 Hydrocephalus Catheters
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Age Group

• 8.1 Infants
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Children
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Adults
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by End User

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Ambulatory Surgical Centers
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Argi Grup
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 CereVasc, Inc.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Christoph Miethke GmbH & Co. KG (B. Braun Group)
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 Hpbio
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Integra LifeSciences Corporation
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 Kaneka Medix Corporation
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Medtronic plc
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Neutral Pharma Pvt. Ltd
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Sophysa
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Spiegelberg GmbH & Co. KG.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio